13F Holdings
中文EN

DNLI Denali Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1714899 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY37.0%
TTM EPS YoY41.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.9%
ROA-27.2%
ROIC (approx.)-50.8%
Asset turnover—

Leverage & solvency

Liabilities / assets26.2%
Debt / equity0.00x
Current ratio6.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.41x
Accruals ratio11.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$330.53M$108.46M$48.66M
R&D expense$418.78M$396.44M$423.88M$358.73M$265.35M
SG&A expense$136.56M$105.44M$103.35M$90.47M$79.06M
Operating income-$555.34M-$487.34M-$196.70M-$340.74M-$295.75M
Income tax$102,000$68,000$30,000$21,000-$575,000
Net income-$512.54M-$422.77M-$145.22M-$325.99M-$290.58M
EBITDA-$544.16M-$479.55M-$179.97M-$330.36M-$287.16M
EPS (basic)-2.97-2.57-1.06-2.60-2.39
EPS (diluted)-2.97-2.57-1.06-2.60-2.39
Weighted avg. shares (diluted)172.65M164.47M137.37M125.53M121.52M
Balance sheet
Cash & equivalents$205.33M$176.53M$128.68M$219.54M$294.98M
Short-term investments$662.55M$657.37M$907.40M$1.12B$571.93M
Receivables$0————
Inventory$0————
Current assets$900.66M$864.44M$1.06B$1.37B$897.23M
PP&E, net$52.40M$55.24M$45.59M$44.09M$38.87M
Intangibles$0————
Total assets$1.14B$1.37B$1.15B$1.46B$1.40B
Current liabilities$98.35M$102.21M$77.98M$363.92M$378.25M
Total liabilities$131.09M$144.50M$122.96M$417.81M$441.87M
Shareholders' equity$1.01B$1.23B$1.03B$1.04B$962.29M
Shares outstanding156.18M144.22M138.39M135.97M122.28M
Cash flow statement
Operating cash flow-$412.60M-$347.69M-$357.99M-$244.72M-$211.39M
Capital expenditure$9.50M$15.91M$12.94M$17.83M$8.50M
Free cash flow-$422.10M-$363.61M-$370.93M-$262.55M-$219.89M
Investing cash flow$255.28M-$88.76M$249.31M-$141.39M-$21.63M
Financing cash flow$189.22M$484.30M$17.82M$310.67M$19.35M
Depreciation & amortization$11.18M$7.79M$16.73M$10.38M$8.59M
Stock-based compensation$99.63M$102.88M$108.10M$99.85M$85.25M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.